The ocular hypotensive efficacy of topical fasudil, a rho-associated protein kinase inhibitor, in patients with end-stage glaucoma

Mohammad Pakravan, Afsaneh Naderi Beni, Elham Ghahari, Reyhaneh Varshochian, Shahin Yazdani, Hamed Esfandiari, Hamid Ahmadieh

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

To investigate the effects of topical administration of a selective Rho-associated kinase (ROCK) inhibitor, fasudil 0.5% and 1.2% in glaucomatous patients. In this interventional case series study, 4 eyes of 4 patients with unilateral end-stage primary open-angle glaucoma and no light perception vision were assigned to receive topical fasudil 0.5% (in 3 eyes) or 1.2% (in 1 eye) ophthalmic solution twice daily for 8 weeks. At weeks 1, 2, 3, 4, and 8, intraocular pressure (IOP) and adverse events were evaluated. Baseline mean IOP was 53.5 6 3.4 mm Hg and mean IOP reductions of the last visit were 28.25 6 1.2 mm Hg at 2 hours and 28.75 6 2.2 mm Hg at 4 hours. Mean IOP reductions were clinically and statistically significant with 0.5% and 1.2% fasudil and peak effects occurred 2-4 hours after application (P = 0.0002). The largest IOP reductions were produced by 1.2% fasudil (up to 212 mm Hg). Conjunctival hyperemia was found in 1 patient with 1.2% fasudil. Topical administration of fasudil in end-stage primary open-angle glaucoma patients, caused reduction in IOP and was well tolerated. ROCK inhibitors could be considered as a candidate for glaucoma therapy in future.

Original languageEnglish (US)
Pages (from-to)E676-E680
JournalAmerican Journal of Therapeutics
Volume24
Issue number6
DOIs
StatePublished - Jan 28 2016
Externally publishedYes

Keywords

  • Glaucoma
  • Intraocular pressure
  • ROCK inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The ocular hypotensive efficacy of topical fasudil, a rho-associated protein kinase inhibitor, in patients with end-stage glaucoma'. Together they form a unique fingerprint.

Cite this